IRIS
NAPOLITANO, Stefania
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 7.106
NA - Nord America 3.393
AS - Asia 3.206
SA - Sud America 399
Continente sconosciuto - Info sul continente non disponibili 261
AF - Africa 41
OC - Oceania 6
Totale 14.412
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 5.116
US - Stati Uniti d'America 3.319
SG - Singapore 1.075
CN - Cina 640
IE - Irlanda 600
IT - Italia 575
HK - Hong Kong 563
VN - Vietnam 392
BR - Brasile 338
DE - Germania 239
KR - Corea 185
GB - Regno Unito 155
IN - India 105
FR - Francia 76
JP - Giappone 72
UA - Ucraina 65
SE - Svezia 50
CA - Canada 46
FI - Finlandia 38
NL - Olanda 35
GR - Grecia 33
BD - Bangladesh 31
TR - Turchia 29
AT - Austria 28
PK - Pakistan 28
PL - Polonia 26
AR - Argentina 22
MX - Messico 20
CZ - Repubblica Ceca 17
BE - Belgio 16
ID - Indonesia 15
IQ - Iraq 12
EC - Ecuador 11
ES - Italia 11
ZA - Sudafrica 11
AZ - Azerbaigian 9
CO - Colombia 7
MA - Marocco 7
UZ - Uzbekistan 7
PY - Paraguay 6
SA - Arabia Saudita 6
VE - Venezuela 6
AU - Australia 5
KE - Kenya 5
TN - Tunisia 5
CH - Svizzera 4
JO - Giordania 4
KG - Kirghizistan 4
KZ - Kazakistan 4
LT - Lituania 4
AE - Emirati Arabi Uniti 3
CR - Costa Rica 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
IL - Israele 3
MK - Macedonia 3
PE - Perù 3
PH - Filippine 3
TH - Thailandia 3
AL - Albania 2
AO - Angola 2
BO - Bolivia 2
CL - Cile 2
EG - Egitto 2
GI - Gibilterra 2
IR - Iran 2
LK - Sri Lanka 2
MY - Malesia 2
SN - Senegal 2
TW - Taiwan 2
UY - Uruguay 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BH - Bahrain 1
BW - Botswana 1
BY - Bielorussia 1
CG - Congo 1
CY - Cipro 1
ET - Etiopia 1
GA - Gabon 1
GE - Georgia 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
IS - Islanda 1
MD - Moldavia 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
RO - Romania 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
Totale 14.151
Salva come PNG Salva come JPEG
Città #
Moscow 1.834
San Jose 636
Dublin 586
Hong Kong 548
Singapore 522
Santa Clara 430
Chandler 282
Ashburn 209
Seoul 184
Naples 150
Ho Chi Minh City 133
Dallas 109
Hefei 109
Jacksonville 109
Beijing 105
Council Bluffs 103
Hanoi 94
New York 92
Los Angeles 89
Munich 69
Bremen 68
Princeton 66
Roxbury 66
Bengaluru 57
The Dalles 53
Caserta 43
Cambridge 37
São Paulo 34
Ann Arbor 33
Medford 29
Da Nang 24
Haiphong 24
Warsaw 24
Chicago 22
Milan 22
Wilmington 20
Nuremberg 19
Brooklyn 18
Tokyo 18
Amsterdam 16
Brno 16
Elora 16
Atlanta 15
Des Moines 15
Rome 15
Vienna 15
Boardman 14
Falkenstein 14
San Francisco 14
Montreal 13
Napoli 13
Brussels 12
Chennai 12
Hải Dương 12
Orem 12
Woodbridge 12
Aversa 11
Houston 11
London 11
Rio de Janeiro 11
Shanghai 11
Lappeenranta 10
Piscataway 10
Turku 10
Baku 9
Belo Horizonte 9
Hillsboro 9
Istanbul 9
Manchester 9
Rawalpindi 9
San Mateo 9
Columbus 8
Ercolano 8
Frankfurt am Main 8
Memphis 8
Ninh Bình 8
Seattle 8
Buffalo 7
Helsinki 7
Jinan 7
Nanjing 7
Tianjin 7
Toronto 7
City of London 6
Denver 6
Dong Ket 6
Mexico City 6
Mumbai 6
Poplar 6
Pozzuoli 6
Rimini 6
Stockholm 6
Tashkent 6
Bahawalpur 5
Battipaglia 5
Biên Hòa 5
Brasília 5
Cape Town 5
Dhaka 5
Düsseldorf 5
Totale 7.639
Salva come PNG Salva come JPEG
Nome #
Beyond N staging in colorectal cancer: Current approaches and future perspectives 226
AXL is an oncotarget in human colorectal cancer 196
Eighth American Joint Committee on Cancer (AJCC) melanoma classification: what about stage IIC? 196
EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer 187
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 185
A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant 184
Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer 179
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. 176
Immunotherapy for head and neck cancer: Present and future 175
Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series 164
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 164
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 164
Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR 163
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment 162
Cetuximab rechallenge plus avelumab in pretreated patients with RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial 162
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials 161
Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions 160
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFRdependent and in cetuximab-resistant human colorectal cancer cells 160
Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients 160
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 155
Multiple Acquired Mutations Captured by Liquid Biopsy in the EGFR Addicted Metastatic Colorectal Cancer 154
Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations 153
Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review 153
CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients 152
Antitumor efficacy of dual blockade with encorafenib plus cetuximab in combination with chemotherapy in human BRAFV600E mutant colorectal cancer 152
Post-Irradiation Breast Angiosarcoma: All the Possible Treatments and Electrochemotherapy. Case Report and Literature Review 151
Biomarker-guided anti-egfr rechallenge therapy in metastatic colorectal cancer 151
Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme 150
Clinical management of metastatic colorectal cancer in the era of precision medicine 150
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer 148
How immunotherapy has changed the continuum of care in hepatocellular carcinoma 148
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 147
Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial 147
Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer. 147
Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC): A single institution experience 147
Pimasertib hydrochloride 146
Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. 145
Immunotherapy in colorectal cancer: is the long-awaited revolution finally happening? 144
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) 143
Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: A case report and a review of literature 142
"RT STRIKES BACK": Radiotherapy in Ultra Elderly with Cutaneous Basal Cell Carcinoma 141
Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAF wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial 141
ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC 140
Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy? 138
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 136
Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells 134
Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer 134
Anti-EGFR-resistant clones decay exponentially after progression: Implications for anti-EGFR re-challenge 134
Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data 133
Panitumumab plus trifluridine/tipiracil as anti‐EGFR rechallenge therapy in patients with refractory RAS wild‐type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial 132
Management of Non-Melanoma Skin Cancer: Radiologists Challenging and Risk Assessment 130
The Role of Adjuvant Therapy for the Treatment of Micrometastases in Endometrial Cancer: A Systematic Review and Meta-Analysis 129
Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer 126
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer 126
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype 126
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models 125
Genetic Landascape of Primary versus metastatic colorectal cancer: to what extent are they concordant ? 125
Previous radiotherapy increases the efficacy of cemiplimab in the treatment of locally advanced and metastatic cutaneous squamous cell carcinoma: A retrospective analysis 123
Prevention of cardiovascular complications in elderly cancer patients 123
PRAME Immunocytochemistry for the Diagnosis of Melanoma Metastases in Cytological Samples 123
Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed? 122
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer 122
Comprehensive Review on the Clinical Relevance of Long Non-Coding RNAs in Cutaneous Melanoma 122
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 122
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets 121
Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer 120
Overexpression of CCL-20 and CXCL-8 genes enhances tumor escape and resistance to cemiplimab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with locally advanced and metastatic cutaneous squamous cell carcinoma 120
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. 119
Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation 118
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients 117
Correction: Ciardiello et al. Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer. Cancers 2021, 13, 1941 117
Now or Later? The Role of Neoadjuvant Treatment in Advanced Endometrial Cancer: A Systematic Review 116
MET ACTIVATION BY AUTOCRINE LOOP RESCUES COLON CANCER CELLS FROM SENSITIVITY TO EGFR INHIBITION 116
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials 116
Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial 115
A retrospective observational study on cutaneous adverse events induced by immune checkpoint inhibitors 114
It is finally time for adjuvant therapy in melanoma 113
Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data 113
Feasibility of next-generation sequencing in clinical practice: Results of a pilot study in the Department of Precision Medicine at the University of Campania ' Luigi Vanvitelli' 112
Hypothalamic–pituitary autoimmunity in patients treated with anti-pd-1 and anti-pd-l1 antibodies 112
Current Landscape and Open Questions on Adjuvant Therapies in Melanoma 112
Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC 111
Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines 109
NMR profiling of Ononis diffusa identifies cytotoxic compounds against cetuximab-resistant colon cancer cell lines 109
MicroRNA Expression in Endometrial Cancer: Current Knowledge and Therapeutic Implications 108
The Role of Sentinel Node Biopsy in the Era of Adjuvant Therapy for Melanoma 108
Treatment of cutaneous melanoma harboring smo p.Gln216arg mutation with imiquimod: An old drug with new results 107
Skin toxicity as predictor of survival in refractory patients with ras wild‐type metastatic colorectal cancer treated with cetuximab and avelumab (Cave) as rechallenge strategy 107
Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression 103
Evaluation of exercise capacity by means of cardiopulmonary exercise testing (CPET) in older adult cancer patients undergoing antineoplastic treatments 103
Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival. 100
How we treat locoregional melanoma 99
Novel in vitro cancer models for optimizing anti- EGFR therapies 97
Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer 96
Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models 95
How we treat metastatic colorectal cancer 95
Predictive Evaluation on Cytological Sample of Metastatic Melanoma: The Role of BRAF Immunocytochemistry in the Molecular Era 95
Resistance Mechanisms to Anti-Epidermal Growth Factor Receptor Therapy in RAS/RAF Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy 94
Obesity correlates to the microsatellite instability of endometrial cancer: A retrospective observational study 93
Sentinel node biopsy in thin melanoma: a retrospective descriptive cohort study 92
Totale 13.448
Salva come PNG Salva come JPEG
Categoria #
all - tutte 49.495
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.495
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022499 0 13 6 4 105 15 38 15 30 59 64 150
2022/20231.193 127 18 32 96 149 97 5 66 545 9 33 16
2023/2024596 61 25 17 23 158 88 18 22 18 14 54 98
2024/20252.156 52 53 30 98 295 295 277 221 265 242 182 146
2025/20269.049 382 448 431 353 743 4.753 565 449 378 284 145 118
2026/2027269 75 194 0 0 0 0 0 0 0 0 0 0
Totale 14.412